Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Other Working Capital
Cash effect of changes in other operating assets and liabilities.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital dips below year-ago levels
Q1 FY2026 other working capital of $1.7M (cash outflow) fell 43.5% year over year, behind the +160.4% change in trailing-twelve-month other working capital.
Context
- Other working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -43.5% toward the trailing-twelve-month pace of +160.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- 117K USD
- Year-over-year change
- -84.9%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 117K | -84.9% |
| FY2024 | 2024-12-31 | 775K | +190.4% |
| FY2023 | 2023-12-31 | (857K) | +36.1% |
| FY2022 | 2022-12-31 | (1.34M) | — |
Other Working Capital vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's LTM Mar 2026 other working capital of $1.42M is the 9th largest of the 11 companies compared; the peer median is $866.05K.
- Its year-over-year change of +160.4% is the 4th highest of 11, against a peer median of +8.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $36.58M | +102.5% | +204.1% | 51.5% | |
| LTM Mar 2026 | $30.25M | -1.6% | +17.6% | 107.2% | |
| LTM Mar 2026 | $9.53M | +273.5% | -25.8% | 4237.3% | |
| LTM Mar 2026 | $4.44M | +18.7% | +149.2% | — | |
| LTM Mar 2026 | $3.95M | -20.5% | -6.1% | 35.2% | |
| LTM Mar 2026 | $3.01M | +193.9% | — | 21.7% | |
| LTM Mar 2026 | $1.89M | +231.5% | — | 3203.4% | |
| LTM Mar 2026 | $1.56M | -89.6% | — | 2.2% | |
| LTM Mar 2026 | $1.42M | +160.4% | — | — | |
ZURAZura Bio Limited | LTM Mar 2026 | $1.1M | -5.4% | — | — |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $631.09K | -90.2% | +306.6% | — |
| Peer median (excluding AARD) | $866.05K | +8.6% | +83.4% | 51.5% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (13.56M) | (7.21M) | (20.59M) | (57.59M) |
| Depreciation & Amortization | 110K | 97K | 16K | (1.31M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 412K | 313K | 439K | 3.95M |
| Change in Working Capital | (1.31M) | (81K) | 1.57M | 356K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 31K | 776K | 798K | 239K |
| Other Working Capital | (1.34M) | (857K) | 775K | 117K |
| Other Non-Cash Items | 3.81M | 1.06M | 473K | 421K |
| Operating Cash Flow | (10.54M) | (5.82M) | (18.09M) | (54.17M) |
| Capital Expenditures | 0 | 0 | (109K) | (95K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (11.89M) | (129.6M) |
| Sales of Investments | 0 | 0 | 0 | 80.03M |
| Other Investing Activities | (1M) | 0 | 0 | 0 |
| Investing Cash Flow | (1M) | 0 | (12M) | (49.67M) |
| Debt Repayment | (1M) | 0 | 0 | 0 |
| Common Stock Issued | 225K | 0 | 332K | 89.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1M | 0 | (3.34M) | 0 |
| Financing Cash Flow | 225K | 0 | 81.99M | 89.25M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | (11.32M) | (5.82M) | 51.91M | (14.59M) |
| Free Cash Flow | (10.54M) | (5.82M) | (18.2M) | (54.27M) |
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.